

A Three-Component Synthesis of Aryl(heteroaryl)acylamides

Supporting information

(part 1)

Rafał Loska,* Patrycja Bukowska

*Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw 42,
Poland*

E-mail: rafal.loska@icho.edu.pl

Contents:

Synthesis and characterization of 1,1-difluorostyrenes.....	S2
Characterization data for α -aryl- α -heteroarylamides 3 , 5 , 9 , 10 , 11	S4
Synthesis and characterization amide 10j	S16
Characterization data for 2-alkylimidazoles 4	S16
Characterization data for side products 6 , 7 , 8	S17
Synthesis and characterization of 1-fluoro-2-(4- <i>tert</i> -butylphenyl)ethene 13	S18
References.....	S19
Copies of NMR spectra.....	S20

Synthesis and characterization of 1,1-difluorostyrenes. 1,1-Difluorostyrenes were obtained using a slightly modified procedure of Fuqua et al.¹ A solution of a carbonyl compound (10 mmol) and triphenylphosphine (12 mmol, 3.15 g) in dry *N,N*-dimethylformamide (7 mL) was prepared in a Schlenk flask in Ar atmosphere. At 100 °C, solid ClCF₂CO₂Na (15 mmol, 2.29 g) was added portionwise over 30 min (**Caution:** too quick addition of ClCF₂CO₂Na can result in an exothermic reaction, decomposition of the product and even loss of some material due to too fast evolution of CO₂). After evolution of carbon dioxide ceased (about 15 – 20 min after the addition of all ClCF₂CO₂Na), the reaction mixture was cooled down and poured into a separation funnel containing hexanes (150 ml). The organic phase was washed with water (150 mL), 30 % H₂O₂ (30 mL) and brine (3 x 100 mL), dried (Na₂SO₄) and evaporated. The product was isolated by column chromatography on silica gel using hexanes or hexanes–AcOEt 10:1 as eluent. Preparation and characterization of compounds **2a**, **2d**, **2f** and **2i** has been described by us recently.² Characterization data for the remaining 1,1-difluorostyrenes **2** is given below.

1,1-Difluoro-2-(4-tert-butylphenyl)ethene (2b),³ obtained in 1.43 g (73%) yield as colourless liquid. IR (film) $\nu_{\max}/\text{cm}^{-1}$ 2965, 1732, 1348, 1251, 1168, 940, 844. ¹H NMR (400 MHz, CDCl₃) δ 1.35 (9H, s), 5.27 (dd, ³J_{HF} = 26.4 Hz, 3.76 Hz), 7.30 (2H, d, ³J_{HH} = 8.2 Hz), 7.39 (2H, d, ³J_{HH} = 8.4 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 31.2, 34.5, 81.8 (dd, ²J_{CF} = 28.9 Hz, 13.9 Hz), 125.6, 127.3 (dd, J_{CF} = 6.6 Hz, 3.7 Hz), 127.5 (m), 150.1 (m), 156.2 (dd, ¹J_{CF} = 297.7 Hz, 287.5 Hz). ¹⁹F NMR (470 MHz, CDCl₃) δ -85.12 (1F, dd, ²J_{FF} = 33.5 Hz, ²J_{FH} = 4.0 Hz), -83.13 (1F, dd, ²J_{FF} = 33.5 Hz, ²J_{FH} = 26.6 Hz). Anal. calcd for C₁₂H₁₄F₂: C, 73.45; H, 7.19; F, 19.36. Found: C, 73.88; H, 6.88; F 18.91.

1,1-Difluoro-2-(4-methoxyphenyl)ethene (2c),⁴ obtained in 0.83 g (49%) yield as colourless liquid. IR (film) $\nu_{\max}/\text{cm}^{-1}$ 2959, 2839, 1734, 1613, 1516, 1299, 1248, 1167, 1037, 938, 839. ¹H NMR (400 MHz, CDCl₃) δ 3.77 (3H, s), 5.18 (1H, dd, ³J_{HF} = 26.4 Hz, 3.8 Hz), 6.86 (2H, dm, ³J_{HH} = 8.8 Hz), 7.23 (2H, dm, ³J_{HH} = 8.9 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 55.2, 81.5 (dd, ²J_{CF} = 29.3 Hz), 114.2, 122.7 (t, ³J_{CF} = 6.2 Hz), 128.8 (dd, ⁴J_{CF} = 6.1 Hz, 3.6 Hz), 155.8 (dd, ¹J_{CF} = 296.3 Hz, 286.5 Hz), 158.6 (m). ¹⁹F NMR (470 MHz, CDCl₃) δ -86.57 (1F, dd, ²J_{FF} = 36.7 Hz, ²J_{FH} = 2.9 Hz), - 84.79 (1F, dd, ²J_{FF} = 36.7 Hz, ²J_{FH} = 26.4 Hz). MS (EI 70 eV, *m/z*, %) 170 (M⁺, 100), 155 (64), 127 (74). HRMS (EI) calcd for C₉H₈OF₂ (M⁺), 170.0543; found, 170.0542. Anal. calcd for C₉H₈OF₂: C, 63.53; H, 4.74; F, 22.33. Found: C, 63.47; H, 4.73; F 22.23.

1,1-Difluoro-2-(2-naphthyl)ethene (2e),⁴ obtained in 1.69 g (89%) yield as white solid, mp 58 – 60 °C. IR (CH₂Cl₂) $\nu_{\max}/\text{cm}^{-1}$ 3059, 1728, 1333, 1256, 1223, 1200, 1168, 97, 935, 860, 742. ¹H NMR (400

MHz, CDCl₃) δ 5.43 (1H, dd, $^3J_{\text{HF}} = 26.2$ Hz, 3.9 Hz), 7.46 (3H, m), 7.75 (1H, s), 7.79 (3H, s). ¹³C NMR (100 MHz, CDCl₃) δ 82.4 (dd, $^2J_{\text{CF}} = 29.2$ Hz, 14.1 Hz), 125.4 (dd, $J_{\text{CF}} = 6.0$ Hz, 2.0 Hz), 126.0, 126.4, 126.6 (m), 127.6, 127.8, 127.8 (m), 128.3, 132.3, 133.4, 156.5 (dd, $^1J_{\text{CF}} = 298.8$ Hz, 288.7 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -83.71 (1F, d, $^2J_{\text{FF}} = 30.1$ Hz), -82.01 (1F, d, $^2J_{\text{FF}} = 30.1$ Hz). Anal. calcd for C₁₂H₈F₂: C, 75.78; H, 4.24; F, 19.98. Found: C, 75.80; H, 4.53; F 19.81.

1,1-Difluoro-2-(4-trifluoromethylphenyl)ethene (2g),⁵ obtained in 0.60 g (29%) yield as colourless liquid. IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 1732, 1623, 1418, 1328, 1253, 1173, 1129, 1070, 1020, 944, 852. ¹H NMR (400 MHz, CDCl₃) δ 5.32 (1H, dd, $^3J_{\text{HF}} = 25.7$ Hz, 3.5 Hz), 7.43 (2H, d, $^3J_{\text{HH}} = 8.2$ Hz), 7.58 (2H, d, $^3J_{\text{HH}} = 8.3$ Hz). ¹³C NMR (100 MHz, CDCl₃) δ 81.6 (dd, $^2J_{\text{CF}} = 29.2$ Hz, 13.1 Hz), 124.0 (q, $^1J_{\text{CF}} = 271.6$ Hz), 125.6 (q, $^3J_{\text{CF}} = 4.0$ Hz), 127.7 (dd, $^4J_{\text{CF}} = 7.0$ Hz, 4.0 Hz), 129.1 (qm, $^2J_{\text{CF}} = 33.2$ Hz), 134.2 (m), 156.8 (dd, $^1J_{\text{CF}} = 299.8$ Hz, 290.7 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -81.44 (1F, d, $^2J_{\text{FF}} = 26.3$ Hz), -79.82 (1F, d, $^2J_{\text{FF}} = 26.3$ Hz), -62.76 (3F, s).

1,1-Difluoro-2-(4-trifluoromethylphenyl)propene (2h),⁶ obtained in 0.58 g (26%) yield as colourless liquid. IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 2940, 1728, 1620, 1328, 1246, 1170, 1129, 1080, 842. ¹H NMR (400 MHz, CDCl₃) δ 1.99 (3H, t, $^4J_{\text{HF}} = 3.4$ Hz), 7.47 (2H, d, $^3J_{\text{HH}} = 8.0$ Hz), 7.60 (2H, d, $^3J_{\text{HH}} = 8.2$ Hz). ¹³C NMR (100 MHz, CDCl₃) δ 12.9, 87.0 (dd, $^2J_{\text{CF}} = 23.6$ Hz, 13.8 Hz), 124.1 (q, $^1J_{\text{CF}} = 272.0$ Hz), 125.3 (q, $^3J_{\text{CF}} = 3.7$ Hz), 127.8 (dd, $^4J_{\text{CF}} = 4.9$ Hz, 3.3 Hz), 129.2 (q, $^2J_{\text{CF}} = 32.3$ Hz), 138.6 (m), 153.9 (dd, $^1J_{\text{CF}} = 292.0$ Hz, 287.6 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -88.85 (1F, d, $^2J_{\text{FF}} = 38.4$ Hz), -88.88 (1F, $^2J_{\text{FF}} = 38.4$ Hz), -62.75 (3F, s). MS (EI 70 eV, *m/z*, %) 222 (M⁺, 100), 203 (19), 191 (42), 189 (50), 173 (50), 151 (37), 145 (39), 133 (27). Anal. calcd for C₁₀H₇F₅: C, 54.06; H, 3.18; F, 42.76. Found: C, 53.94; H, 2.94; F, 42.56.

1,1,3,3,3-Pentafluoro-2-(4-tert-butylphenyl)propene (2j), obtained in 1.56 g (59%) as colourless liquid. IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 2968, 1356, 1256, 1174, 1134, 1013, 957, 834, 713, 632, 561. ¹H NMR (400 MHz, CDCl₃) δ 1.33 (9H, s), 7.26 (2H, d, $^3J_{\text{HH}} = 8.3$ Hz), 7.43 (2H, $^3J_{\text{HH}} = 8.2$ Hz). ¹³C NMR (100 MHz, CDCl₃) δ 31.4, 34.9, 90.0 (m), 123.1, 124.2 (qdd, $^1J_{\text{CF}} = 271.6$ Hz, $^3J_{\text{CF}} = 11.2$ Hz, 6.0 Hz), 125.9, 129.8, 152.7, 156.4 (ddq, $^1J_{\text{CF}} = 306.1$ Hz, 292.3 Hz, $^3J_{\text{CF}} = 3.5$ Hz). ¹⁹F NMR (470 MHz, CDCl₃) δ -59.30 (3F, dd, $^4J_{\text{FF}} = 24.3$ Hz, 11.1 Hz), -75.98 (1F, dq, $^2J_{\text{FF}} = 12.49$ Hz, $^4J_{\text{FF}} = 24.1$ Hz), -77.91 (1F, m). MS (EI 70 eV, *m/z*, %) 264 (M⁺, 32), 250 (24), 249 (100), 241 (14), 221 (44), 41 (32). HRMS (EI) calcd for C₁₃H₁₃F₅ (M⁺), 264.0937; found, 264.0946. Anal. calcd for C₁₃H₁₃F₅: C, 59.09; H, 4.96; F, 35.95. Found: C, 59.04; H, 4.92; F, 36.02.

Characterization data for α -aryl- α -heteroarylamides **3**, **5**, **9**, **10**, **11**

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(1-naphthyl)acetic acid N-(4-methylphenyl)amide (3a).

Colourless crystals (204 mg, 89%), mp 184–186 °C (toluene–CH₂Cl₂). *R_f* 0.36 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\max}/\text{cm}^{-1}$ 3176, 3026, 2918, 2858, 1678, 1608, 1555, 1521, 1437, 1310, 810, 776, 474. ¹H NMR (500 MHz, CDCl₃) δ 2.00 (3H, s), 2.26 (3H, s), 2.32 (3H, s), 4.65 (1H, d, ²*J*_{HH} = 17.1 Hz), 4.74 (1H, d, ²*J*_{HH} = 17.1 Hz), 5.66 (1H, s), 6.69 (2H, m), 7.05 (2H, d, ³*J*_{HH} = 8.2 Hz), 7.14 (3H, m), 7.32 (1H, t, ³*J*_{HH} = 7.5 Hz), 7.47 (4H, m), 7.53 (1H, t, ³*J*_{HH} = 7.1 Hz), 7.68 (1H, d, ³*J*_{HH} = 8.1 Hz), 7.79 (1H, d, ³*J*_{HH} = 8.1 Hz), 8.39 (1H, d, ³*J*_{HH} = 8.5 Hz), 12.06 (1H, s). ¹³C NMR (125 MHz, CDCl₃) δ 8.8, 12.7, 20.8, 46.2, 46.7, 119.9, 123.4, 124.0, 125.3, 125.5, 125.8, 126.0, 126.7, 127.6, 128.2, 128.6, 128.7, 129.2, 131.4, 131.8, 133.2, 134.0, 134.1, 135.6, 136.2, 143.5, 167.0. HRMS (ESI) calcd for C₃₁H₃₀N₃O ([M+H]⁺), 460.2389; found, 460.2390. Anal. calcd for C₃₁H₂₉N₃O: C, 81.02; H, 6.36; N, 9.14. Found: C, 81.05; H, 6.11; N 9.06.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(4-tert-butylphenyl)acetic acid N-(4-methylphenyl)amide (3b).

Pale yellow oil (194 mg, 83%). *R_f* 0.49 (hexanes–AcOEt 2:1). IR (CH₂Cl₂) $\nu_{\max}/\text{cm}^{-1}$ 3186, 3029, 2962, 2866, 1682, 1610, 1554, 1514, 1442, 1314, 1267, 817, 730. ¹H NMR (500 MHz, CDCl₃) δ 1.32 (9H, s), 2.06 (3H, s), 2.34 (3H, s), 2.35 (3H, s), 4.87 (1H, s), 4.95 (2H, AB, ²*J*_{HH} = 17.1 Hz), 6.86 (2H, m), 7.15 (2H, d, ³*J*_{HH} = 8.2 Hz), 7.25 (3H, m), 7.32 (4H, m), 7.60 (2H, d, ³*J*_{HH} = 8.3 Hz), 12.21 (1H, bs). ¹³C NMR (125 MHz, CDCl₃) δ 8.7, 12.6, 20.8, 31.2, 34.3, 46.6, 50.6, 119.7, 123.0, 125.55, 125.6, 127.47, 127.49, 128.7, 129.1, 131.5, 133.1, 134.7, 135.8, 136.1, 143.2, 150.0, 167.1. HRMS (ESI) calcd for C₃₁H₃₆N₃O ([M+H]⁺), 466.2858; found, 466.2870.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(4-methoxyphenyl)acetic acid N-(4-methylphenyl)amide (3c).

Colourless crystals (50 mg, 23%), mp 144–146 °C (isooctane–CH₂Cl₂). *R_f* 0.22 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\max}/\text{cm}^{-1}$ 3024, 2918, 2858, 1675, 1609, 1557, 1509, 1439, 1318, 1254, 1175, 1106, 1036, 821, 726. ¹H NMR (500 MHz, CDCl₃) δ 2.01 (3H, s), 2.28 (3H, s), 2.29 (3H, s), 3.73 (3H, s), 4.93 (3H, m), 6.75 (2H, d, ³*J*_{HH} = 8.7 Hz), 6.80 (2H, m), 7.08 (2H, d, ³*J*_{HH} = 8.2 Hz), 7.22 (5H, m), 7.51 (2H, d, ³*J*_{HH} = 8.3 Hz), 11.92 (1H, bs). ¹³C NMR (125 MHz, CDCl₃) δ 8.8, 12.4, 20.8, 46.9, 49.8, 55.3, 114.2, 114.3, 119.8, 119.9, 125.7, 127.7, 128.9, 129.0, 129.1, 129.2, 129.2, 133.4, 136.1, 143.3, 159.0, 167.1. HRMS (ESI) calcd for C₂₈H₃₀N₃O₂ ([M+H]⁺), 440.2338; found, 440.2333. Anal. calcd for C₂₈H₂₉N₃O₂: C, 76.51; H, 6.65; N, 9.56. Found: C, 76.39; H, 6.88; N 9.52.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(4-methoxycarbonylphenyl)acetic acid N-(4-methylphenyl)amide (3d). Colourless crystals (163 mg, 70%), mp 137–138 °C (isooctane–CH₂Cl₂). *R_f* 0.29 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\max}/\text{cm}^{-1}$ 3242, 3185 3117, 3029, 2950, 2921, 2857, 1723, 1682, 1608, 1551, 1513, 1436, 1279, 1180, 1108, 1020, 818, 734. ¹H NMR (200 MHz, CDCl₃) δ 2.03 (3H, s), 2.28 (3H, s), 2.30 (3H, s), 3.86 (3H, s), 4.84 (1H, s), 4.85 (2H, AB, ²*J*_{HH} = 17.3 Hz), 6.78 (2H, m), 7.08 (2H, d, ³*J*_{HH} = 8.3 Hz), 7.19 (3H, m), 7.38 (2H, d, ³*J*_{HH} = 8.3 Hz), 7.49 (2H, d, ³*J*_{HH} = 8.3 Hz), 7.88 (2H, d, ³*J*_{HH} = 8.3 Hz), 12.12 (1H, s). ¹³C NMR (50 MHz, CDCl₃) δ 8.7, 12.7, 20.8, 46.6, 50.9, 52.0, 119.8, 123.4, 125.5, 127.7, 127.9, 128.8, 129.1, 129.2, 129.8, 131.9, 133.4, 135.5, 135.8, 142.2, 142.6, 166.1, 166.6. MS (EI 70 eV, *m/z*, %) 334 (100), 243 (80), 184 (24), 91 (31). HRMS (ESI) calcd for C₂₉H₃₀N₃O₃ ([M+H]⁺), 468.2287; found, 468.2281. Anal. calcd for C₂₉H₂₉N₃O₃: C, 74.50; H, 6.25; N, 8.99. Found: C, 74.64; H, 6.12; N 9.06.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(1-naphthyl)acetic acid N,N-diethylamide (5a). Pale yellow oil (160 mg, 75%). *R_f* 0.20 (AcOEt). IR (neat) $\nu_{\max}/\text{cm}^{-1}$ 3060, 2970, 2929, 1643, 1427, 1360, 1309, 1218, 1136, 1079, 792, 728. ¹H NMR (500 MHz, CDCl₃) δ 1.01 (3H, t, ³*J*_{HH} = 7.1 Hz), 1.21 (3H, t, ³*J*_{HH} = 7.1 Hz), 1.87 (3H, s), 2.21 (3H, s), 3.08 (2H, m), 3.33 (1H, dq, ²*J*_{HH} = 13.5, ³*J*_{HH} = 7.0 Hz), 3.61 (1H, dq, ²*J*_{HH} = 13.5 Hz, ³*J*_{HH} = 6.9 Hz), 4.77 (1H, d, ²*J*_{HH} = 17.5 Hz), 5.42 (1H, d, ²*J*_{HH} = 17.5 Hz), 6.12 (1H, s), 6.18 (2H, d, ³*J*_{HH} = 7.5 Hz), 6.75 (2H, m), 6.89 (1H, d, ³*J*_{HH} = 7.3 Hz), 7.14 (1H, t, ³*J*_{HH} = 7.6 Hz), 7.31 (1H, d, ³*J*_{HH} = 7.1 Hz), 7.39 (1H, t, ³*J*_{HH} = 6.9 Hz), 7.45 (2H, m), 7.65 (1H, d, ³*J*_{HH} = 7.8 Hz), 8.09 (1H, d, ³*J*_{HH} = 8.3 Hz). ¹³C NMR (125 MHz, CDCl₃) δ 8.8, 12.8, 14.1, 40.4, 42.3, 47.7, 48.0, 123.8, 124.2, 124.8, 124.9, 125.5, 125.8, 126.1, 126.5, 127.7, 128.3, 128.7, 131.6, 132.0, 133.9, 136.2, 143.0, 169.4. MS (EI 70 eV, *m/z*, %) 425 (M⁺, 13), 325 (100), 233 (20), 91 (25). HRMS (EI) calcd for C₂₈H₃₁N₃O (M⁺), 425.2467; found, 425.2463.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(4-tert-butylphenyl)acetic acid N,N-diethylamide (5b). Pale yellow oil (174 mg, 81%). *R_f* 0.25 (AcOEt). IR (neat) $\nu_{\max}/\text{cm}^{-1}$ 3026, 2964, 2866, 1646, 1493, 1452, 1427, 1362, 1310, 1249, 1221, 1133, 809, 745, 723. ¹H NMR (500 MHz, CDCl₃) δ 1.04 (3H, t, ³*J*_{HH} = 7.1 Hz), 1.15 (3H, m), 1.16 (9H, s), 1.88 (3H, s), 2.19 (3H, s), 3.16 (2H, m), 3.30 (1H, dq, ²*J*_{HH} = 13.6 Hz, ³*J*_{HH} = 7.0 Hz), 3.52 (1H, dq, ²*J*_{HH} = 13.6 Hz, ³*J*_{HH} = 7.1 Hz), 4.86 (1H, d, ²*J*_{HH} = 17.3 Hz), 5.40 (1H, d, ²*J*_{HH} = 17.5 Hz), 5.56 (1H, bs), 6.54 (2H, m), 7.06 (3H, m), 7.10 (4H, s). ¹³C NMR (100 MHz, CDCl₃) δ 8.9, 12.5, 12.8, 14.2, 31.2, 34.2, 40.4, 42.3, 47.9, 49.5, 124.2, 125.3, 125.4, 126.6, 127.9, 128.0, 131.6, 133.0, 136.8, 143.6, 149.8, 168.8. HRMS (ESI) calcd for C₂₈H₃₈N₃O ([M+H]⁺), 432.3015; found, 432.3020.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(4-methoxyphenyl)acetic acid N,N-diethylamide (5c). Pale yellow oil (73 mg, 36%). R_f 0.16 (AcOEt). IR (CH₂Cl₂) $\nu_{\max}/\text{cm}^{-1}$ 2969, 2929, 1644, 1512, 1431, 1304, 1250, 1178, 1033, 811, 731. ¹H NMR (500 MHz, CDCl₃) δ 1.00 (3H, t, ³ J_{HH} = 7.1 Hz), 1.14 (3H, t, ³ J_{HH} = 7.1 Hz), 1.93 (3H, s), 2.20 (3H, s), 3.14 (2H, m), 3.31 (1H, dq, ² J_{HH} = 13.6 Hz, ³ J_{HH} = 7.0 Hz), 3.48 (1H, dq, ² J_{HH} = 13.6 Hz, ³ J_{HH} = 7.0 Hz), 3.66 (3H, s), 4.90 (1H, d, ² J_{HH} = 17.3 Hz), 5.30 (1H, d, ² J_{HH} = 17.2 Hz), 5.51 (1H, bs), 6.60 (2H, m), 6.63 (2H, d, ³ J_{HH} = 8.7 Hz), 7.07 (2H, d, ³ J_{HH} = 8.6 Hz), 7.12 (3H, m). ¹³C NMR (125 MHz, CDCl₃) δ 8.9, 12.3, 12.8, 14.2, 40.5, 42.4, 47.8, 48.7, 55.1, 114.0, 124.4, 125.5, 126.8, 128.2, 129.5, 131.5, 136.6, 137.5, 143.5, 158.7, 168.7. HRMS (ESI) calcd for C₂₅H₃₂N₃O₂ ([M+H]⁺), 406.2495; found, 406.2496.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(4-methoxycarbonylphenyl)acetic acid N,N-diethylamide (5d). Pale yellow oil (22 mg, 10%). IR (CH₂Cl₂) $\nu_{\max}/\text{cm}^{-1}$ 2925, 1721, 1650, 1432, 1280, 1110, 758. ¹H NMR (400 MHz, CDCl₃) δ 0.95 (3H, t, ³ J_{HH} = 7.1 Hz), 1.13 (3H, t, ³ J_{HH} = 7.1 Hz), 1.98 (3H, s), 2.19 (3H, s), 3.08 (2H, m), 3.32 (1H, m), 3.44 (1H, m), 3.87 (3H, s), 4.91 (1H, d, ² J_{HH} = 17.3 Hz), 5.08 (1H, d, ² J_{HH} = 17.5 Hz), 5.37 (1H, s), 6.65 (2H, m), 7.13 (3H, m), 7.20 (2H, d, ³ J_{HH} = 8.3 Hz), 7.79 (2H, d, ³ J_{HH} = 8.3 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 9.0, 12.76, 12.80, 14.2, 40.6, 42.3, 47.5, 49.60, 52.0, 124.3, 124.8, 125.5, 127.0, 128.4, 128.6, 129.0, 129.8, 136.6, 141.7, 142.5, 166.7, 168.0. HRMS (ESI) calcd for C₂₆H₃₂N₃O₃ ([M+H]⁺), 434.2444; found, 434.2437.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(1-naphthyl)acetic acid N-benzylamide (9a). Pale yellow oil (125 mg, 54%). R_f 0.17 (hexanes–AcOEt 2:1). IR (neat) $\nu_{\max}/\text{cm}^{-1}$ 3201, 3030, 2918, 1667, 1598, 1550, 1496, 1435, 1354, 1306, 1219, 1029, 778, 725, 695. ¹H NMR (500 MHz, CDCl₃) δ 1.99 (3H, s), 2.23 (3H, s), 4.46 (2H, m), 4.71 (2H, AB, ² J_{HH} = 17.0 Hz), 5.62 (1H, s), 6.71 (2H, m), 7.12 (3H, m), 7.16–7.26 (5H, m), 7.31 (1H, t, ³ J_{HH} = 7.7 Hz), 7.40 (1H, d, ³ J_{HH} = 7.1 Hz), 7.48 (2H, m), 7.69 (1H, d, ³ J_{HH} = 8.1 Hz), 7.79 (1H, d, ³ J_{HH} = 7.8 Hz), 8.30 (1H, d, ³ J_{HH} = 8.4 Hz), 9.44 (1H, bs). ¹³C NMR (125 MHz, CDCl₃) δ 8.8, 12.8, 43.4, 46.4, 46.7, 123.2, 123.9, 125.3, 125.6, 125.8, 126.1, 126.6, 126.9, 127.3, 127.5, 128.2, 128.3, 128.6, 128.7, 131.7, 131.8, 133.9, 134.0, 135.8, 138.6, 143.3, 169.5. MS (EI 70 eV, m/z , %) 459 (M⁺, 22), 326 (100), 235 (81), 91 (41). HRMS (EI) calcd for C₃₁H₂₉N₃O (M⁺), 459.2311; found, 459.2304.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(1-naphthyl)acetic acid N-tert-butylamide (9b). Colourless crystals (172 mg, 81%), mp 161–163 °C (isooctane–CH₂Cl₂). R_f 0.20 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\max}/\text{cm}^{-1}$ 3214, 3059, 2964, 2920, 2868, 1946, 1809, 1670, 1565, 1453, 1434, 1390, 1362, 1301, 1224,

1030, 793, 779, 728, 693, 450. ¹H NMR (500 MHz, CDCl₃) δ 1.32 (9H, s), 1.97 (3H, s), 2.24 (3H, s), 4.71 (2H, s), 5.44 (1H, s), 6.66 (2H, m), 7.11 (3H, m), 7.32 (1H, t, ³J_{HH} = 7.8 Hz), 7.42 (2H, m), 7.47 (1H, tm, ³J_{HH} = 6.9 Hz), 7.65 (1H, d, ³J_{HH} = 8.1 Hz), 7.76 (1H, d, ³J_{HH} = 7.6 Hz), 8.24 (1H, d, ³J_{HH} = 8.4 Hz), 9.16 (1H, bs). ¹³C NMR (125 MHz, CDCl₃) δ 8.8, 12.8, 28.5, 46.6, 46.9, 51.1, 123.0, 124.0, 125.3, 125.5, 125.6, 125.8, 126.5, 127.3, 127.9, 128.6, 128.6, 131.7, 131.9, 134.9, 134.5, 135.8, 143.9, 168.4. HRMS (ESI) calcd for C₂₈H₃₂N₃O ([M+H]⁺), 426.2545; found, 426.2547. Anal. calcd for C₂₈H₃₁N₃O: C, 79.02; H, 7.34; N, 9.87. Found: C, 79.13; H, 7.32; N 9.70.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(1-naphthyl)acetic acid N-(2-pyridyl)amide (9c). Colourless crystals (130 mg, 58%), mp 196–197 °C (isooctane–CH₂Cl₂). *R*_f 0.18 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\max}/\text{cm}^{-1}$ 2918, 1661, 1575, 1548, 1429, 1303, 869, 781, 729. ¹H NMR (400 MHz, CDCl₃) δ 2.03 (3H, s), 2.35 (3H, s), 4.63 (1H, d, ²J_{HH} = 17.1 Hz), 4.76 (1H, d, ²J_{HH} = 17.2 Hz), 6.73 (2H, m), 6.94 (1H, dd, ³J_{HH} = 6.6 Hz, 5.1 Hz), 7.15 (3H, m), 7.34 (1H, t, ³J_{HH} = 7.8 Hz), 7.47 (1H, t, ³J_{HH} = 7.5 Hz), 7.53 (3H, m), 7.71 (1H, d, ³J_{HH} = 8.2 Hz), 7.80 (1H, d, ³J_{HH} = 8.0 Hz), 8.08 (1H, d, ³J_{HH} = 8.4 Hz), 8.31 (1H, d, ³J_{HH} = 3.9 Hz), 8.35 (1H, d, ³J_{HH} = 8.6 Hz), 12.0 (1H, s). ¹³C NMR (100 MHz, CDCl₃) δ 8.8, 12.9, 46.6, 46.7, 114.4, 119.4, 123.4, 123.7, 125.5, 125.6, 125.8, 126.4, 126.8, 127.6, 128.4, 128.7, 131.6, 132.1, 133.5, 134.1, 135.7, 137.8, 142.8, 148.0, 152.0, 168.0. HRMS (ESI) calcd for C₂₉H₂₇N₄O ([M+H]⁺), 447.2185; found, 447.2204.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(1-naphthyl)acetic acid N,O-dimethylhydroxamide (9d). Pale yellow crystals (135 mg, 65%), mp 147–149 °C (toluene–CH₂Cl₂). *R*_f 0.28 (AcOEt). IR (KBr) $\nu_{\max}/\text{cm}^{-1}$ 3060, 2919, 1674, 1598, 1427, 1377, 1173, 997, 794, 729. ¹H NMR (500 MHz, CDCl₃) δ 1.98 (3H, s), 2.23 (3H, s), 3.23 (3H, s), 3.36 (3H, s), 4.76 (1H, d, ²J_{HH} = 17.1 Hz), 4.97 (1H, d, ²J_{HH} = 16.1 Hz), 6.28 (1H, bs), 6.54 (2H, bs), 7.03 (3H, m), 7.25 (1H, t, ³J_{HH} = 6.8 Hz), 7.29 (1H, d, ³J_{HH} = 7.3 Hz), 7.43 (2H, m), 7.61 (1H, d, ³J_{HH} = 7.9 Hz), 7.74 (1H, d, ³J_{HH} = 8.4 Hz), 7.93 (1H, d, ³J_{HH} = 7.6 Hz). ¹³C NMR (125 MHz, CDCl₃) δ 8.9, 12.9, 32.6, 44.9, 47.3, 61.3, 123.1, 123.7, 125.2, 125.4, 125.6, 125.6, 126.4, 126.8, 126.9, 128.2, 128.8, 131.8, 132.2, 132.4, 133.9, 136.3, 142.5, 171.0. MS (EI 70 eV, *m/z*, %) 413 (M⁺, 16), 353 (16), 325 (100), 233 (27), 91 (32). HRMS (EI) calcd for C₂₆H₂₇N₃O₂ (M⁺), 413.2103; found, 413.2110. Anal. calcd for C₂₆H₂₇N₃O₂: C, 75.52; H, 6.58; N, 10.16. Found: C, 75.43; H, 6.61; N 10.05.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(2-naphthyl)acetic acid N,O-dimethylhydroxamide (9e). Prepared from alkene **2e** (10.5 mmol, 2.00 g), N-oxide **1a** (12.6 mmol, 2.55 g) and N,O-dimethylhydroxylamine hydrochloride (12.6 mmol, 1.23 g) in the presence of NEt₃ (4.7 mL) in 3.59 g (82%) yield, pale yellow crystals, mp 52–54 °C (isooctane–CH₂Cl₂). *R*_f 0.18 (AcOEt). IR (KBr)

$\nu_{\max}/\text{cm}^{-1}$ 3056, 2919, 1672, 1601, 1495, 1428, 1377, 1304, 1173, 998, 814, 734. ^1H NMR (500 MHz, CDCl_3) δ 1.98 (3H, s), 2.23 (3H, s), 3.20 (3H, s), 3.37 (3H, s), 4.85 (1H, d, $^2J_{\text{HH}} = 17.0$ Hz), 4.99 (1H, d, $^2J_{\text{HH}} = 17.0$ Hz), 5.66 (1H, s), 6.75 (2H, m), 7.08 (3H, m), 7.34 (1H, d, $^3J_{\text{HH}} = 8.4$ Hz), 7.39 (2H, m), 7.56 (1H, s), 7.68 (3H, m). ^{13}C NMR (125 MHz, CDCl_3) δ 8.9, 12.8, 32.6, 47.2, 47.8, 61.2, 123.6, 125.6, 125.7, 125.8, 127.06, 127.09, 127.4, 127.6, 127.8, 128.1, 128.3, 132.2, 132.6, 133.2, 133.6, 136.4, 142.7, 170.0. HRMS (ESI) calcd for $\text{C}_{26}\text{H}_{28}\text{N}_3\text{O}_2$ ($[\text{M}+\text{H}]^+$), 414.2182 found, 414.2185. Anal. calcd for $\text{C}_{26}\text{H}_{27}\text{N}_3\text{O}_2$: C, 75.52; H, 6.58; N, 10.16. Found: C, 75.43; H, 6.56; N 10.14.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(1-naphthyl)acetic acid N-(2-methylphenyl)amide (9f).

Colourless crystals (62 mg, 27%), mp 167–169 °C (isooctane– CH_2Cl_2). R_f 0.51 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\max}/\text{cm}^{-1}$ 3239, 3185, 3122, 3033, 2918, 1675, 1617, 1591, 1556, 1486, 1456, 1430, 1308, 1264, 794, 768, 728. ^1H NMR (400 MHz, CDCl_3) δ 2.01 (3H, s), 2.30 (3H, s), 2.46 (3H, s), 4.70 (2H, AB, $^2J_{\text{HH}} = 17.1$ Hz), 5.70 (1H, s), 6.71 (2H, m), 6.95 (1H, t, $^3J_{\text{HH}} = 7.4$ Hz), 7.07 (1H, t, $^3J_{\text{HH}} = 7.7$ Hz), 7.14 (4H, m), 7.33 (1H, t, $^3J_{\text{HH}} = 7.7$ Hz), 7.42–7.57 (3H, m), 7.69 (1H, d, $^3J_{\text{HH}} = 8.1$ Hz), 7.79 (1H, d, $^3J_{\text{HH}} = 8.0$ Hz), 8.01 (1H, d, $^3J_{\text{HH}} = 8.0$ Hz), 8.42 (1H, d, $^3J_{\text{HH}} = 8.5$ Hz), 11.96 (1H, bs). ^{13}C NMR (100 MHz, CDCl_3) δ 8.8, 12.6, 18.7, 46.5, 46.7, 121.6, 123.4, 123.9, 124.0, 125.3, 125.6, 125.8, 126.0, 126.3, 126.7, 127.6, 128.3, 128.4, 128.6, 128.7, 130.2, 131.4, 131.8, 134.10, 134.14, 135.6, 137.1, 143.5, 167.3. MS (EI 70 eV, m/z , %) 459 (M^+ , 1), 326 (100), 235 (91), 91 (20). HRMS (EI) calcd for $\text{C}_{31}\text{H}_{29}\text{N}_3\text{O}$ (M^+), 459.2311; found, 459.2327. Anal. calcd for $\text{C}_{31}\text{H}_{29}\text{N}_3\text{O}$: C, 81.02; H, 6.36; N, 9.14. Found: C, 81.13; H, 6.32; N 9.11.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(1-naphthyl)acetic acid N-(2-aminophenyl)amide (9g).

Colourless crystals (160 mg, 69%), mp 79–81 °C (isooctane– CH_2Cl_2). R_f 0.09 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\max}/\text{cm}^{-1}$ 3348, 3197, 3032, 2918, 2858, 1681, 1597, 1496, 1456, 1304, 1030, 779, 746. ^1H NMR (500 MHz, CDCl_3) δ 2.02 (3H, s), 2.26 (3H, s), 4.52 (2H, bs), 4.74 (2H, AB, $^2J_{\text{HH}} = 17.0$ Hz), 5.76 (1H, s), 6.61 (1H, t, $^3J_{\text{HH}} = 7.6$ Hz), 6.69 (1H, dd, $^3J_{\text{HH}} = 7.9$ Hz, $^4J_{\text{HH}} = 0.8$ Hz), 6.75 (2H, m), 6.95 (1H, td, $^3J_{\text{HH}} = 7.6$ Hz, $^4J_{\text{HH}} = 1.1$ Hz), 7.13 (4H, m), 7.29 (1H, d, $^3J_{\text{HH}} = 6.9$ Hz), 7.33 (1H, t, $^3J_{\text{HH}} = 7.9$ Hz), 7.50 (1H, t, $^3J_{\text{HH}} = 7.0$ Hz), 7.55 (1H, t, $^3J_{\text{HH}} = 7.0$ Hz), 7.73 (1H, d, $^3J_{\text{HH}} = 8.0$ Hz), 7.83 (1H, d, $^3J_{\text{HH}} = 7.9$ Hz), 8.32 (1H, d, $^3J_{\text{HH}} = 8.4$ Hz), 9.49 (1H, s). ^{13}C NMR (125 MHz, CDCl_3) δ 8.9, 12.6, 47.0, 48.3, 116.1, 117.9, 123.2, 123.6, 123.7, 125.4, 125.8, 125.96, 125.98, 126.1, 126.8, 127.0, 127.6, 128.68, 128.70, 128.74, 131.7, 132.3, 133.4, 134.0, 135.4, 141.5, 143.1, 168.1. HRMS (ESI) calcd for $\text{C}_{30}\text{H}_{29}\text{N}_4\text{O}$ (M^+), 461.2341; found, 461.2338. Anal. calcd for $\text{C}_{30}\text{H}_{28}\text{N}_4\text{O}$: C, 78.23; H, 6.13; N, 12.16; Found: C, 77.95; H, 6.14; N 11.91.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(1-naphthyl)acetamide (9h). Colourless crystals (62 mg, 34%), mp 168–170 °C (isooctane–CH₂Cl₂). *R_f* 0.26 (AcOEt). IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$ 3234, 3060, 2921, 1666, 1596, 1483, 1428, 1389, 1356, 1302, 1030, 899, 778, 722. ¹H NMR (400 MHz, CDCl₃) δ 1.98 (3H, s), 2.24 (3H, s), 4.64 (1H, AB, ²*J*_{HH} = 17.1 Hz), 4.73 (1H, AB, ²*J*_{HH} = 17.1 Hz), 5.52 (1H, s), 5.89 (1H, bs), 6.69 (2H, m), 7.11 (3H, m), 7.30 (1H, t, ³*J*_{HH} = 7.8 Hz), 7.40 (1H, m), 7.45 (2H, m), 7.67 (1H, d, ³*J*_{HH} = 8.04 Hz), 7.77 (1H, d, ³*J*_{HH} = 7.6 Hz), 8.20 (1H, d, ³*J*_{HH} = 8.2 Hz), 8.63 (1H, bs). ¹³C NMR (100 MHz, CDCl₃) δ 8.8, 12.7, 46.71, 46.73, 123.3, 123.6, 125.3, 125.6, 125.7, 126.1, 126.6, 127.4, 128.2, 128.6, 128.6, 131.6, 131.9, 133.6, 133.9, 135.7, 143.1, 171.9. MS (EI 70 eV, *m/z*, %) 369 (M⁺, 24), 325 (100), 235 (91), 91 (74). HRMS (EI) calcd for C₂₄H₂₃N₃O (M⁺), 369.1841; found, 369.1845. Anal. calcd for C₂₄H₂₃N₃O: C, 78.02; H, 6.27; N, 11.37. Found: C, 77.76; H, 6.24; N 11.39.

Amide 9i. Colourless crystals (135 mg, 56%), mp 182–184 °C (isooctane–CH₂Cl₂). *R_f* 0.55 (AcOEt). IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$ 3031, 2949, 2919, 2858, 1721, 1662, 1600, 1481, 1434, 1395, 1280, 1181, 1107, 1021, 755, 730. ¹H NMR (500 MHz, CDCl₃) δ 2.03 (3H, s), 2.20 (3H, s), 2.93–3.04 (2H, m), 3.62 (1H, m), 3.84 (1H, m), 3.88 (3H, s), 5.00 (2H, AB, ²*J*_{HH} = 17.2 Hz), 5.39 (1H, s), 6.72 (2H, m), 7.00 (1H, t, ³*J*_{HH} = 7.4 Hz), 7.13 (5H, m), 7.27 (2H, d, ³*J*_{HH} = 9.0 Hz), 7.84 (2H, d, ³*J*_{HH} = 8.1 Hz), 8.20 (1H, d, ³*J*_{HH} = 8.0 Hz). ¹³C NMR (125 MHz, CDCl₃) δ 9.0, 12.7, 27.9, 47.5, 47.9, 52.0, 52.2, 117.6, 124.0, 124.4, 124.5, 125.6, 127.2, 127.4, 128.4, 128.5, 128.8, 129.3, 129.9, 131.2, 136.2, 140.7, 141.6, 142.9, 166.6, 166.8. MS (EI 70 eV, *m/z*, %) 479 (M⁺, 39), 333 (47), 243 (29), 227 (100), 91 (85). HRMS (EI) calcd for C₃₀H₂₉N₃O₃ (M⁺), 479.2209; found, 479.2209. Anal. calcd for C₃₀H₂₉N₃O₃: C, 75.13; H, 6.10; N, 8.76. Found: C, 74.90; H, 6.07; N 8.78.

2-(4,5-Dimethyl-1-p-tolylimidazol-2-yl)-2-(1-naphthyl)acetic acid N-(4-methylphenyl)amide (9j). Pale yellow crystals (230 mg, >95%), mp 158–159 °C (isooctane–CH₂Cl₂). *R_f* 0.48 (hexanes–AcOEt 2:1). IR (CH₂Cl₂) $\nu_{\text{max}}/\text{cm}^{-1}$ 3039, 2920, 1682, 1609, 1550, 1514, 1429, 1314, 1254, 817, 794, 775. ¹H NMR (400 MHz, CDCl₃) δ 1.88 (3H, s), 2.27 (3H, s), 2.28 (3H, s), 2.32 (3H, s), 5.51 (1H, s), 6.11 (1H, bs), 6.65 (1H, bs), 7.06 (2H, d, ³*J*_{HH} = 8.4 Hz), 7.14 (1H, bs), 7.24 (1H, bs), 7.28–7.41 (3H, m), 7.49 (2H, d, ³*J*_{HH} = 8.4 Hz), 7.68 (2H, m), 7.75 (1H, d, ³*J*_{HH} = 7.4 Hz), 7.87 (1H, d, ³*J*_{HH} = 8.5 Hz), 11.59 (1H, bs). ¹³C NMR (100 MHz, CDCl₃) δ 9.1, 12.8, 20.8, 21.0, 46.3, 119.8, 123.9, 124.0, 125.3, 125.4, 126.0, 127.4, 127.9, 128.3, 129.2, 129.8, 130.0, 131.4, 131.8, 132.8, 133.2, 134.0, 134.6, 136.1, 138.9, 143.9, 167.3. HRMS (ESI) calcd for C₃₁H₃₀N₃O ([M+H]⁺), 460.2389; found, 460.2383. Anal. calcd for C₃₁H₂₉N₃O: C, 81.02; H, 6.36; N, 9.14. Found: C, 81.05; H, 6.34; N 9.11.

2-[5-(4-chlorophenyl)-1-n-propylimidazol-2-yl]-2-(1-naphthyl)acetic acid N-(4-methylphenyl)amide

(9k). Colourless crystals (224 mg, 91%), mp 192–193 °C (isooctane–CH₂Cl₂). *R_f* 0.49 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\max}/\text{cm}^{-1}$ 3227, 3178, 3046, 2962, 1665, 1608, 1552, 1512, 1490, 1433, 1316, 1169, 1133, 1092, 1013, 836, 804, 776, 664. ¹H NMR (500 MHz, CDCl₃) δ 0.46 (3H, t, ³*J*_{HH} = 7.4 Hz), 1.07 (1H, m), 1.30 (1H, m), 2.27 (3H, s), 3.62 (1H, m), 3.70 (1H, m), 5.98 (1H, s), 7.06 (2H, d, ³*J*_{HH} = 8.2 Hz), 7.12 (1H, s), 7.24 (2H, d, ³*J*_{HH} = 8.4 Hz), 7.38 (2H, d, ³*J*_{HH} = 8.5 Hz), 7.41 (1H, m), 7.49 (2H, d, ³*J*_{HH} = 8.4 Hz), 7.52 (1H, t, ³*J*_{HH} = 7.5 Hz), 7.65 (2H, m), 7.79 (1H, d, ³*J*_{HH} = 8.2 Hz), 7.87 (1H, d, ³*J*_{HH} = 8.1 Hz), 8.60 (1H, d, ³*J*_{HH} = 8.6 Hz), 11.22 (1H, bs). ¹³C NMR (125 MHz, CDCl₃) δ 10.7, 20.8, 23.8, 45.5, 46.9, 120.0, 123.5, 125.4, 125.9, 126.0, 126.1, 127.1, 128.4, 128.6, 128.9, 129.0, 129.2, 130.4, 131.7, 132.7, 133.4, 133.6, 134.2, 134.6, 135.8, 146.1, 166.8. MS (EI 70 eV, *m/z*, %) 493 (M⁺, 2), 360 (100), 317 (30), 303 (14), 219 (10), 192 (12). HRMS (EI) calcd for C₃₁H₂₈N₃OCl (M⁺), 493.1921; found, 493.1933. Anal. calcd for C₃₁H₂₈N₃OCl: C, 75.37; H, 5.71; N, 8.51; Cl, 7.18. Found: C, 75.60; H, 5.92; N 8.53; Cl, 6.99.

2-[5-(4-methoxyphenyl)-1-n-propylimidazol-2-yl]-2-(1-naphthyl)acetic acid N-(4-methylphenyl)amide (9l). Colourless crystals (222 mg, 91%), mp 187–188 °C (isooctane–CH₂Cl₂). *R_f* 0.38 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\max}/\text{cm}^{-1}$ 3227, 3175, 3042, 2963, 1668, 1609, 1552, 1509, 1477, 1315, 1251, 1177, 1032, 837, 803, 775. ¹H NMR (500 MHz, CDCl₃) δ 0.46 (3H, t, ³*J*_{HH} = 7.4 Hz), 1.07 (1H, m), 1.30 (1H, m), 2.27 (3H, s), 3.61 (1H, m), 3.69 (1H, m), 3.82 (3H, s), 6.00 (1H, s), 6.93 (2H, d, ³*J*_{HH} = 8.7 Hz), 7.06 (2H, m), 7.07 (1H, s), 7.22 (2H, d, ³*J*_{HH} = 8.7 Hz), 7.41 (1H, t, ³*J*_{HH} = 7.7 Hz), 7.51 (3H, m), 7.66 (2H, m), 7.78 (1H, d, ³*J*_{HH} = 8.2 Hz), 7.87 (1H, d, ³*J*_{HH} = 8.1 Hz), 8.62 (1H, d, ³*J*_{HH} = 8.6 Hz), 11.38 (1H, bs). ¹³C NMR (125 MHz, CDCl₃) δ 10.8, 20.8, 23.8, 45.4, 46.8, 55.3, 114.2, 120.0, 122.0, 123.6, 125.0, 125.5, 125.9, 126.1, 127.1, 128.5, 128.9, 129.2, 130.7, 131.7, 133.5, 133.6, 133.7, 134.2, 135.9, 145.2, 159.8, 166.9. MS (EI 70 eV, *m/z*, %) 489 (M⁺, 7), 356 (100), 314 (24), 299 (11), 188 (15). HRMS (EI) calcd for C₃₂H₃₁N₃O₂ (M⁺), 489.2416; found, 489.2425. Anal. calcd for C₃₂H₃₁N₃O₂: C, 78.50; H, 6.38; N, 8.58. Found: C, 78.36; H, 6.40; N 8.60.

2-(2-thiazolyl)-2-(1-naphthyl)acetic acid N-(4-methylphenyl)amide (9m). Pale yellow oil (30 mg, 17%). *R_f* 0.30 (hexanes–AcOEt 2:1). IR (neat) $\nu_{\max}/\text{cm}^{-1}$ 3268, 3046, 2920, 1684, 1662, 1604, 1513, 1403, 1314, 1245, 1170, 1124, 1057, 789, 729. ¹H NMR (400 MHz, CDCl₃) δ 2.29 (3H, s), 6.05 (1H, s), 7.08 (2H, d, ³*J*_{HH} = 8.4 Hz), 7.28 (1H, d, ³*J*_{HH} = 3.6 Hz), 7.42 (2H, d, ³*J*_{HH} = 8.4 Hz), 7.48 (3H, m), 7.69 (1H, d, ³*J*_{HH} = 7.6 Hz), 7.85 (3H, m), 8.11 (1H, m), 9.68 (1H, s). ¹³C NMR (100 MHz, CDCl₃) δ 20.8, 53.4, 120.0, 120.1, 123.6, 125.5, 126.0, 126.9, 127.1, 129.0, 129.2, 129.4, 131.3, 133.8, 134.0, 134.3, 135.3, 142.0, 166.9, 169.0. HRMS (ESI) calcd for C₂₂H₁₉N₂OS ([M+H]⁺), 359.1218; found, 359.1223.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(4-trifluoromethylphenyl)propionic acid N-(4-methylphenyl)amide (10a). Pale yellow oil (92 mg, 37%). R_f 0.72 (hexanes–AcOEt 1:1). IR (KBr) $\nu_{\max}/\text{cm}^{-1}$ 3302, 3028, 2920, 2854, 2809, 1659, 1611, 1513, 1411, 1326, 1166, 1118, 1069, 1016, 814, 731. ^1H NMR (500 MHz, CDCl_3) δ 1.92 (3H, s), 1.98 (3H, s), 2.30 (3H, s), 2.32 (3H, s), 4.58 (2H, s), 6.65 (2H, m), 7.09 (2H, d, $^3J_{\text{HH}} = 8.3$ Hz), 7.18 (3H, m), 7.34 (2H, d, $^3J_{\text{HH}} = 8.3$ Hz), 7.44 (2H, d, $^3J_{\text{HH}} = 8.2$ Hz), 7.48 (2H, d, $^3J_{\text{HH}} = 8.3$ Hz), 12.93 (1H, bs). ^{13}C NMR (125 MHz, CDCl_3) δ 8.9, 12.5, 20.9, 25.5, 47.9, 52.1, 120.1, 125.0, 125.1, 125.4 (q, $^3J_{\text{CF}} = 3.5$ Hz), 126.2 (q, $^1J_{\text{CF}} = 208.5$ Hz), 127.4, 127.5, 128.6, 129.29, 129.33 (q, $^2J_{\text{CF}} = 32.9$ Hz), 130.3, 133.6, 135.6, 136.1, 146.5, 147.0, 169.9. ^{19}F NMR (470 MHz, CDCl_3) δ -62.59 (s). HRMS (ESI) calcd for $\text{C}_{29}\text{H}_{29}\text{F}_3\text{N}_3\text{O}$ ($[\text{M}+\text{H}]^+$), 492.2263; found, 492.2268. Anal. calcd for $\text{C}_{29}\text{H}_{28}\text{F}_3\text{N}_3\text{O}$: C, 70.86; H, 5.74; N, 8.55; F, 11.60. Found: C, 71.07; H, 5.97; N 8.74; F, 11.63.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(4-trifluoromethylphenyl)propionic acid N,N-diethylamide (10b). Pale yellow oil (83 mg, 36%). R_f 0.62 (hexanes–AcOEt 1:1). IR (CH_2Cl_2) $\nu_{\max}/\text{cm}^{-1}$ 2976, 2937, 1632, 1455, 1409, 1328, 1273, 1166, 1122, 1080, 1017, 841, 731. ^1H NMR (500 MHz, CDCl_3) δ 0.60 (3H, t, $^3J_{\text{HH}} = 6.9$ Hz), 1.12 (3H, t, $^3J_{\text{HH}} = 6.9$ Hz), 1.77 (3H, s), 1.95 (3H, s), 2.22 (3H, s), 2.72 (1H, dq, $^2J_{\text{HH}} = 14.5$ Hz, $^3J_{\text{HH}} = 7.1$ Hz), 3.06 (2H, m), 3.40 (1H, dq, $^2J_{\text{HH}} = 14.5$ Hz, $^3J_{\text{HH}} = 7.1$ Hz), 4.85 (1H, d, $^2J_{\text{HH}} = 17.6$ Hz), 5.21 (1H, d, $^2J_{\text{HH}} = 17.6$ Hz), 6.86 (2H, m), 7.21 (1H, m), 7.26 (2H, m), 7.54 (4H, m). ^{13}C NMR (125 MHz, CDCl_3) δ 11.7, 15.2, 15.5, 15.8, 33.0, 44.3, 46.1, 50.3, 56.1, 126.8 (q, $^1J_{\text{CF}} = 272.4$ Hz), 127.1, 127.5 (q, $^3J_{\text{CF}} = 3.4$ Hz), 128.0, 129.8, 131.0, 131.3 (m), 131.2, 134.9, 139.1, 148.3, 150.6, 173.6. ^{19}F NMR (470 MHz, CDCl_3) δ -62.56 (s). HRMS (ESI) calcd for $\text{C}_{26}\text{H}_{31}\text{N}_3\text{OF}_3$ ($[\text{M}+\text{H}]^+$), 458.2419; found, 458.2418.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(3-nitrophenyl)propionic acid N-(4-methylphenyl)amide (10c). Pale yellow oil (100 mg, 43%). R_f 0.33 (hexanes–AcOEt 2:1). IR (CH_2Cl_2) $\nu_{\max}/\text{cm}^{-1}$ 3028, 2923, 2859, 1675, 1610, 1530, 1406, 1349, 1312, 1106, 735. ^1H NMR (400 MHz, CDCl_3) δ 1.94 (3H, s), 2.03 (3H, s), 2.31 (3H, s), 2.33 (3H, s), 4.61 (2H, AB, $^2J_{\text{HH}} = 18.6$ Hz), 6.59 (2H, m), 7.11 (2H, d, $^3J_{\text{HH}} = 8.4$ Hz), 7.14 (3H, m), 7.34 (1H, t, $^3J_{\text{HH}} = 7.9$ Hz), 7.48 (2H, d, $^3J_{\text{HH}} = 8.2$ Hz), 7.62 (1H, dm, $^3J_{\text{HH}} = 7.8$ Hz), 7.93 (1H, dm, $^3J_{\text{HH}} = 7.3$ Hz), 8.05 (1H, t, $^4J_{\text{HH}} = 1.9$ Hz), 12.92 (1H, bs). ^{13}C NMR (100 MHz, CDCl_3) δ 8.9, 12.7, 20.9, 25.7, 47.8, 52.0, 120.1, 122.2, 122.6, 125.0, 125.1, 127.4, 128.6, 129.3, 129.5, 130.7, 133.2, 133.7, 135.2, 135.9, 144.6, 146.4, 148.1, 169.8. MS (EI 70 eV, m/z , %) 335 (77), 244 (100), 198 (24), 123 (14), 106 (27), 91 (97). HRMS (ESI) calcd for $\text{C}_{28}\text{H}_{29}\text{N}_4\text{O}_3$ ($[\text{M}+\text{H}]^+$), 469.2240; found, 469.2243.

2-(4,5-Dimethyl-1-p-tolylimidazol-2-yl)-2-(3-nitrophenyl)propionic acid N-(4-methylphenyl)amide (10d). Colourless crystals (117 mg, 33% from 0.75 mmol of **2i**), mp 171–173 °C (isooctane–CH₂Cl₂). *R_f* 0.45 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\max}/\text{cm}^{-1}$ 2915, 1667, 1608, 1533, 1510, 1403, 1349, 1107, 1003, 823, 723. ¹H NMR (400 MHz, CDCl₃) δ 1.73 (3H, s), 1.92 (3H, s), 2.28 (3H, s), 2.30 (3H, s), 2.32 (3H, s), 5.91 (1H, d, ³*J*_{HH} = 8.0 Hz), 6.72 (1H, d, ³*J*_{HH} = 7.8 Hz), 6.91 (1H, d, ³*J*_{HH} = 7.9 Hz), 7.14 (3H, m), 7.32 (1H, t, ³*J*_{HH} = 8.0 Hz), 7.43 (1H, d, ³*J*_{HH} = 7.8 Hz), 7.54 (2H, d, ³*J*_{HH} = 8.3 Hz), 7.81 (1H, s), 8.00 (1H, d, ³*J*_{HH} = 8.0 Hz), 13.03 (1H, s). ¹³C NMR (100 MHz, CDCl₃) δ 9.2, 12.6, 20.9, 20.9, 25.3, 52.4, 120.1, 121.7, 122.2, 126.2, 127.9, 128.3, 128.9, 129.4, 129.5, 129.7, 129.9, 133.6, 133.8, 134.2, 136.1, 139.1, 145.5, 146.9, 148.1, 170.4. HRMS (ESI) calcd for C₂₈H₂₉N₄O₃ ([M+H]⁺), 469.2240; found, 469.2243. Anal. calcd for C₂₈H₂₈N₄O₃: C, 71.78; H, 6.02; N, 11.96. Found: C, 71.69; H, 5.94; N, 12.02.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(3-nitrophenyl)propionic acid N,O-dimethylhydroxamide (10e). Pale yellow oil (46 mg, 22%). *R_f* 0.38 (AcOEt). IR (CH₂Cl₂) $\nu_{\max}/\text{cm}^{-1}$ 3033, 2933, 2864, 1649, 1529, 1452, 1410, 1350, 1308, 1178, 1108, 994, 807, 737, 690. ¹H NMR (500 MHz, CDCl₃) δ 2.03 (3H, s), 2.07 (3H, s), 2.29 (3H, s), 2.80 (3H, s), 3.25 (3H, s), 4.85 (2H, AB, ²*J*_{HH} = 17.6 Hz), 6.80 (2H, m), 7.19 (3H, m), 7.38 (2H, m), 8.00 (1H, dm, ³*J*_{HH} = 7.5 Hz), 8.03 (1H, m). ¹³C NMR (125 MHz, CDCl₃) δ 9.1, 12.8, 27.5, 33.3, 47.7, 52.9, 60.2, 121.7, 123.4, 124.6, 125.6, 127.2, 128.35, 128.45, 132.2, 134.0, 135.6, 144.8, 145.6, 147.8, 168.8. MS (EI 70 eV, *m/z*, %) 422 (M⁺, 15), 334 (100), 191 (11), 91 (81). HRMS (EI) calcd for C₂₃H₂₆N₄O₄ (M⁺), 422.1954; found, 422.1954.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(3-nitrophenyl)propionic acid N-(3-chloro-4-methoxyphenyl)amide (10f). Yellow oil (113 mg, 44%). *R_f* 0.19 (hexanes–AcOEt 2:1). IR (CH₂Cl₂) $\nu_{\max}/\text{cm}^{-1}$ 2924, 1673, 1604, 1529, 1501, 1405, 1349, 1283, 1063, 1022, 807, 734, 696. ¹H NMR (500 MHz, CDCl₃) δ 1.94 (3H, s), 2.03 (3H, s), 2.33 (3H, s), 3.86 (3H, s), 4.61 (2H, AB, ²*J*_{HH} = 17.7 Hz), 6.59 (2H, m), 6.86 (1H, d, ³*J*_{HH} = 8.9 Hz), 7.14 (3H, m), 7.35 (1H, t, ³*J*_{HH} = 7.9 Hz), 7.45 (1H, dd, ³*J*_{HH} = 8.8 Hz, ⁴*J*_{HH} = 2.4 Hz), 7.59 (1H, d, ³*J*_{HH} = 7.7 Hz), 7.71 (1H, d, ⁴*J*_{HH} = 2.4 Hz), 7.93 (1H, d, ³*J*_{HH} = 8.2 Hz), 8.03 (1H, s), 13.3 (1H, bs). ¹³C NMR (125 MHz, CDCl₃) δ 8.9, 12.6, 25.6, 47.9, 51.9, 56.4, 112.2, 119.6, 122.3, 122.5, 124.9, 125.2, 126.7, 127.4, 128.6, 128.9, 129.4, 130.6, 132.3, 133.1, 135.1, 144.4, 146.2, 148.1, 151.7, 169.9. MS (EI 70 eV, *m/z*, %) 335 (85), 244 (100), 198 (27), 91 (73). HRMS (ESI) calcd for C₂₈H₂₈N₄O₄Cl ([M+H]⁺), 519.1799; found, 519.1802.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(3-nitrophenyl)propionic acid N-(methoxycarbonylmethyl)amide (10g). Pale yellow oil (97 mg, 43%). *R_f* 0.40 (AcOEt). IR (CH₂Cl₂)

$\nu_{\max}/\text{cm}^{-1}$ 3348, 2993, 2925, 2860, 1752, 1667, 1529, 1407, 1350, 1208, 1019, 736, 696. ^1H NMR (400 MHz, CDCl_3) δ 1.95 (3H, s), 2.00 (3H, s), 2.28 (3H, s), 3.74 (3H, s), 3.89 (1H, dd, $^2J_{\text{HH}} = 18.2$ Hz, $^3J_{\text{HH}} = 5.3$ Hz), 4.00 (1H, dd, $^2J_{\text{HH}} = 18.2$ Hz, $^3J_{\text{HH}} = 5.2$ Hz), 4.67 (2H, AB, $^2J_{\text{HH}} = 17.8$ Hz), 6.56 (2H, m), 7.12 (3H, m), 7.30 (1H, t, $^3J_{\text{HH}} = 8.1$ Hz), 7.60 (1H, dm, $^3J_{\text{HH}} = 7.8$ Hz), 7.88 (1H, dm, $^3J_{\text{HH}} = 8.2$ Hz), 8.04 (1H, t, $^4J_{\text{HH}} = 2.1$ Hz), 9.89 (1H, t, $^3J_{\text{HH}} = 4.7$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 8.9, 12.7, 26.5, 41.6, 47.7, 51.8, 52.2, 122.0, 122.7, 124.9, 125.2, 127.2, 128.4, 129.1, 131.4, 133.3, 135.3, 144.3, 145.8, 147.9, 170.1, 172.5. HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{27}\text{N}_4\text{O}_5$ ($[\text{M}+\text{H}]^+$), 451.1981; found, 451.1976.

2-(1-Benzyl-4,5-dimethylimidazol-2-yl)-2-(3-nitrophenyl)propionic acid N-(2-fluoro-6-trifluoromethylbenzyl)amide (10h). Pale yellow crystals (197 mg, 71%), mp 100–102 °C (toluene– CH_2Cl_2). R_f 0.23 (hexanes–AcOEt 2:1). IR (CH_2Cl_2) $\nu_{\max}/\text{cm}^{-1}$ 2925, 1670, 1530, 1350, 1318, 1167, 1124, 803, 725. ^1H NMR (400 MHz, CDCl_3) δ 1.89 (3H, s), 1.93 (3H, s), 2.18 (3H, s), 4.56 (1H, dd, $^2J_{\text{HH}} = 14.7$ Hz, $^3J_{\text{HH}} = 5.1$ Hz), 4.59 (2H, s), 4.72 (1H, dd, $^2J_{\text{HH}} = 14.6$ Hz, $^3J_{\text{HH}} = 5.6$ Hz), 6.55 (2H, m), 7.12 (3H, m), 7.30 (2H, m), 7.42 (1H, m), 7.50 (1H, d, $^3J_{\text{HH}} = 7.8$ Hz), 7.58 (1H, dm, $^3J_{\text{HH}} = 7.8$ Hz), 7.88 (1H, dm, $^3J_{\text{HH}} = 8.2$ Hz), 7.97 (1H, t, $^4J_{\text{HH}} = 2.1$ Hz), 10.42 (1H, bs). ^{13}C NMR (100 MHz, CDCl_3) δ 8.8, 12.4, 25.8, 33.9, 47.6, 51.7, 119.5 (d, $^2J_{\text{CF}} = 23.3$ Hz), 121.8 (m), 121.9, 122.2, 122.6, 123.9 (d, $^2J_{\text{CF}} = 19.0$ Hz), 124.9, 127.2, 127.8 (q, $^1J_{\text{CF}} = 206.0$ Hz), 128.4, 129.1, 130.9 (m), 131.0, 133.2, 135.3, 144.5, 146.1, 147.9, 162.0 (d, $^1J_{\text{CF}} = 250.0$ Hz), 171.5. ^{19}F NMR (470 MHz, CDCl_3) δ -112.74 (1F, dd, $^3J_{\text{FH}} = 8.6$ Hz, $^4J_{\text{HH}} = 6.2$ Hz), -58.84 (3F, s). MS (EI 70 eV, m/z , %) 555 ($[\text{M}+\text{H}]^+$, 33), 335 (98), 244 (99), 202 (29), 177 (52), 91 (100). HRMS (ESI) calcd for $\text{C}_{29}\text{H}_{27}\text{F}_4\text{N}_4\text{O}_3$ ($[\text{M}+\text{H}]^+$), 555.2019; found, 555.2023. Anal. calcd for $\text{C}_{29}\text{H}_{26}\text{F}_4\text{N}_4\text{O}_3$: C, 62.81; H, 4.73; F, 13.70; N, 10.10. Found: C, 62.92; H, 4.86; F, 13.66; N, 10.01.

2-(4,5-Dimethyl-1-p-tolylimidazol-2-yl)-2-(4-tert-butylphenyl)-3,3,3-trifluoropropionic acid N-(4-methylphenyl)amide (10i). Colourless crystals (220 mg, 55% from 0.75 mmol of **2j**), mp 178–180 °C (isooctane– CH_2Cl_2). R_f 0.72 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\max}/\text{cm}^{-1}$ 2961, 2869, 1908, 1690, 1610, 1555, 1513, 1445, 1399, 1240, 1211, 1157, 1110, 1046, 944, 822, 665, 564, 514. ^1H NMR (500 MHz, CDCl_3) δ 1.26 (9H, s), 1.65 (3H, s), 2.24 (3H, s), 2.32 (6H, s), 6.03 (1H, d, $^3J_{\text{HH}} = 7.5$ Hz), 6.59 (1H, d, $^3J_{\text{HH}} = 7.7$ Hz), 6.78 (1H, d, $^3J_{\text{HH}} = 7.3$ Hz), 6.92 (2H, d, $^3J_{\text{HH}} = 7.9$ Hz), 6.97 (1H, d, $^3J_{\text{HH}} = 7.8$ Hz), 7.02 (2H, d, $^3J_{\text{HH}} = 8.2$ Hz), 7.13 (2H, d, $^3J_{\text{HH}} = 7.9$ Hz), 7.54 (2H, d, $^3J_{\text{HH}} = 8.0$ Hz), 12.74 (1H, bs). ^{13}C NMR (125 MHz, CDCl_3) δ 9.4, 12.6, 20.9, 21.0, 31.2, 34.3, 63.0 (q, $^2J_{\text{CF}} = 25.2$ Hz), 120.0, 124.3 (q, $^1J_{\text{CF}} = 286.7$ Hz), 125.0, 127.86, 127.94, 128.0, 128.6, 128.7, 129.2, 129.3, 130.8, 132.2, 133.8, 134.1,

135.8, 137.5, 139.7, 150.2, 163.7. ^{19}F NMR (376 MHz, CDCl_3) δ -63.30 (s). HRMS (ESI) calcd for $\text{C}_{32}\text{H}_{35}\text{N}_3\text{OF}_3$ ($[\text{M}+\text{H}]^+$), 534.2732; found, 534.2748. Anal. calcd for $\text{C}_{32}\text{H}_{34}\text{F}_3\text{N}_3\text{O}$: C, 72.02; H, 6.42; F, 10.68; N, 7.87. Found: C, 72.01; H, 6.48; F, 10.66; N, 7.73.

2-(4-Methylquinolin-2-yl)-2-(4-tert-butylphenyl)acetic acid N-(4-methylphenyl)amide (IIa). Yellow crystals (161 mg, 76%), mp 164–166 °C (isooctane– CH_2Cl_2). R_f 0.51 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$ 3163, 3021, 2958, 1680, 1597, 1541, 1509, 1443, 1410, 1364, 1312, 1255, 1168, 1108, 1028, 905, 813, 758. ^1H NMR (500 MHz, CDCl_3) δ 1.24 (9H, s), 2.29 (3H, s), 2.65 (3H, s), 5.20 (1H, s), 7.10 (2H, d, $^3J_{\text{HH}} = 8.2$ Hz), 7.24 (1H, s), 7.30 (2H, d, $^3J_{\text{HH}} = 8.4$ Hz), 7.46 (2H, d, $^3J_{\text{HH}} = 8.4$ Hz), 7.56 (2H, d, $^3J_{\text{HH}} = 8.3$ Hz), 7.58 (1H, m), 7.76 (1H, tm, $^3J_{\text{HH}} = 7.6$ Hz), 7.97 (1H, d, $^3J_{\text{HH}} = 8.1$ Hz), 8.19 (1H, d, $^3J_{\text{HH}} = 8.3$ Hz), 11.46 (1H, bs). ^{13}C NMR (125 MHz, CDCl_3) δ 18.8, 20.8, 31.2, 34.4, 60.1, 119.8, 123.4, 123.9, 125.7, 126.6, 127.1, 127.8, 128.9, 129.3, 129.9, 133.3, 135.8, 136.0, 146.0, 146.4, 150.2, 158.7, 168.4. MS (EI 70 eV, m/z , %) 422 (M^+ , 2), 315 (6), 289 (100), 274 (63), 106 (22). HRMS (EI) calcd for $\text{C}_{29}\text{H}_{30}\text{N}_2\text{O}$ (M^+), 422.2358; found, 422.2365. Anal. calcd for $\text{C}_{29}\text{H}_{30}\text{N}_2\text{O}$: C, 82.43; H, 7.16; N, 6.63. Found: C, 82.20; H, 7.25; N 6.48.

2-(4-Methylquinolin-2-yl)-2-(3-nitrophenyl)acetic acid N-(4-methylphenyl)amide (IIb). Pale yellow crystals (170 mg, 83%), mp 103–104 °C (isooctane– CH_2Cl_2). R_f 0.28 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$ 3249, 3033, 2921, 1652, 1603, 1526, 1348, 1250, 1166, 1096, 818, 760, 434, 703. ^1H NMR (500 MHz, CDCl_3) δ 2.30 (3H, s), 2.71 (3H, s), 5.37 (1H, s), 7.12 (2H, d, $^3J_{\text{HH}} = 8.3$ Hz), 7.27 (1H, s), 7.47 (1H, t, $^3J_{\text{HH}} = 8.0$ Hz), 7.53 (2H, d, $^3J_{\text{HH}} = 8.3$ Hz), 7.64 (1H, t, $^3J_{\text{HH}} = 7.3$ Hz), 7.83 (1H, t, $^3J_{\text{HH}} = 7.6$ Hz), 7.93 (1H, d, $^3J_{\text{HH}} = 7.8$ Hz), 8.03 (1H, d, $^3J_{\text{HH}} = 8.4$ Hz), 8.09 (1H, dm, $^3J_{\text{HH}} = 8.2$ Hz), 8.24 (1H, d, $^3J_{\text{HH}} = 8.4$ Hz), 8.41 (1H, s), 11.45 (1H, bs). ^{13}C NMR (125 MHz, CDCl_3) δ 18.9, 20.8, 59.5, 119.9, 122.5, 123.0, 123.4, 124.0, 127.2, 127.2, 128.8, 129.5, 129.6, 130.5, 134.0, 134.5, 135.5, 140.7, 146.0, 147.7, 148.4, 157.1, 166.8. MS (EI 70 eV, m/z , %) 411 (M^+ , 2), 278 (100), 232 (28), 217 (19). HRMS (EI) calcd for $\text{C}_{25}\text{H}_{21}\text{N}_3\text{O}_3$ (M^+), 411.1583; found, 411.1594. Anal. calcd for $\text{C}_{25}\text{H}_{21}\text{N}_3\text{O}_3$: C, 72.98; H, 5.14; N, 10.21. Found: C, 73.10; H, 5.07; N 10.12.

2-(1-Isoquinolinyl)-2-(4-tert-butylphenyl)acetic acid N,N-diethylamide (IIc). Pale yellow oil (122 mg, 65%). R_f 0.25 (hexanes–AcOEt 2:1). IR (CH_2Cl_2) $\nu_{\text{max}}/\text{cm}^{-1}$ 2965, 1648, 1428, 1362, 1271, 1134, 827, 732. ^1H NMR (400 MHz, CDCl_3) δ 0.94 (1H, t, $^3J_{\text{HH}} = 7.0$ Hz), 1.16 (1H, t, $^3J_{\text{HH}} = 7.0$ Hz), 1.26 (9H, s), 3.17 (2H, m), 3.46 (2H, m), 5.99 (1H, s), 7.22 (2H, d, $^3J_{\text{HH}} = 8.2$ Hz), 7.29 (2H, d, $^3J_{\text{HH}} = 8.3$ Hz), 7.50 (1H, t, $^3J_{\text{HH}} = 7.4$ Hz), 7.55 (1H, d, $^3J_{\text{HH}} = 5.6$ Hz), 7.60 (1H, t, $^3J_{\text{HH}} = 7.3$ Hz), 7.79 (1H, d, $^3J_{\text{HH}} = 8.1$ Hz), 8.14 (1H, d, $^3J_{\text{HH}} = 8.5$ Hz), 8.53 (1H, d, $^3J_{\text{HH}} = 5.7$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 12.7, 13.9,

31.3, 34.3, 40.3, 41.8, 54.9, 120.1, 125.2, 125.2, 126.8, 127.3, 127.5, 129.1, 129.7, 135.2, 136.8, 142.0, 149.5, 158.4, 170.0. HRMS (EI) calcd for C₂₅H₃₁N₂O ([M+H]⁺), 375.2436; found, 375.2448.

2-[6-(2-pyridyl)-pyrid-2-yl]-2-(3-nitrophenyl)acetic acid N-(4-methylphenyl)amide (IId). White solid (25 mg, 12%), mp 139–141 °C (isooctane–CH₂Cl₂). *R_f* 0.23 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\max}/\text{cm}^{-1}$ 3308, 3276, 3240, 3126, 3061, 2920, 1904, 1671, 1658, 1607, 1580, 1527, 1455, 1428, 1344, 1253, 1151, 1095, 991, 861, 810, 775, 726, 692. ¹H NMR (400 MHz, CDCl₃) δ 2.28 (3H, s), 5.24 (1H, s), 7.09 (2H, d, ³*J*_{HH} = 8.2 Hz), 7.40 (4H, m), 7.51 (1H, t, ³*J*_{HH} = 8.0 Hz), 7.91 (3H, m), 8.13 (1H, dm, ³*J*_{HH} = 8.2 Hz), 8.42 (2H, dm, ³*J*_{HH} = 7.9 Hz), 8.50 (1H, m), 8.77 (1H, dm, ³*J*_{HH} = 4.7 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 20.8, 60.3, 119.8, 120.6, 120.7, 122.5, 123.3, 124.4, 124.8, 129.5, 129.6, 134.1, 134.6, 135.2, 137.3, 139.2, 140.8, 148.5, 149.8, 155.1, 156.0, 156.5, 166.9. MS (EI 70 eV, *m/z*, %) 291 (100), 261 (13), 244 (32), 167 (13). HRMS (ESI) calcd for C₂₅H₂₁N₄O₃ (M⁺), 425.1614; found, 425.1619.

2-(4-tert-butylpyridin-2-yl)-2-(4-trifluoromethylphenyl)acetic acid N-(4-methylphenyl)amide (IIe). Yellow oil (64 mg, 30%). *R_f* 0.24 (hexanes–AcOEt 2:1). IR (CH₂Cl₂) $\nu_{\max}/\text{cm}^{-1}$ 3278, 3032, 2967, 1683, 1601, 1542, 1515, 1406, 1326, 1165, 1126, 1068, 1019, 819, 737. ¹H NMR (400 MHz, CDCl₃) δ 1.30 (9H, s), 2.28 (3H, s), 5.12 (1H, s), 7.09 (2H, d, ³*J*_{HH} = 8.2 Hz), 7.28 (1H, dd, ³*J*_{HH} = 5.4 Hz, ⁴*J*_{HH} = 1.7 Hz), 7.34 (1H, d, ⁴*J*_{HH} = 1.3 Hz), 7.46 (2H, d, ³*J*_{HH} = 8.4 Hz), 7.54 (2H, d, ³*J*_{HH} = 8.4 Hz), 7.60 (2H, d, ³*J*_{HH} = 8.4 Hz), 8.59 (1H, d, ³*J*_{HH} = 5.4 Hz), 10.69 (1H, s). ¹³C NMR (100 MHz, CDCl₃) δ 20.8, 30.4, 34.9, 60.9, 119.9, 120.0, 122.0, 124.0 (q, ¹*J*_{CF} = 271.9 Hz), 125.6 (q, ³*J*_{CF} = 3.8 Hz), 128.4, 129.4, 129.5 (q, ²*J*_{CF} = 32.3 Hz), 133.8, 135.6, 143.2, 148.8, 157.4, 162.4, 167.7. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.57 (s). HRMS (ESI) calcd for C₂₅H₂₆N₂OF₃ ([M+H]⁺), 427.1997; found, 427.1990.

Amide II f. Pale yellow oil (37 mg, 18%). *R_f* 0.15 (hexanes–AcOEt 2:1). 2,5-Substituted regioisomer (major): IR (CH₂Cl₂) $\nu_{\max}/\text{cm}^{-1}$ 2952, 1721, 1688, 1657, 1590, 1481, 1402, 1280, 1109, 1021, 757, 732. ¹H NMR (400 MHz, CDCl₃) δ 2.60 (3H, s), 3.13 (2H, m), 3.91 (3H, s), 3.96 (1H, dt, ²*J*_{HH} = 6.5 Hz, ³*J*_{HH} = 10.2 Hz), 4.24 (1H, dt, ²*J*_{HH} = 6.9 Hz, ³*J*_{HH} = 10.1 Hz), 5.62 (1H, s), 7.04 (1H, t, ³*J*_{HH} = 7.4 Hz), 7.18 (2H, m), 7.39 (1H, d, ³*J*_{HH} = 8.3 Hz), 7.52 (2H, d, ³*J*_{HH} = 8.3 Hz), 8.05 (2H, d, ³*J*_{HH} = 8.4 Hz), 8.17 (1H, dd, ³*J*_{HH} = 8.3 Hz, ⁴*J*_{HH} = 2.3 Hz), 8.28 (1H, d, ³*J*_{HH} = 8.0 Hz), 9.09 (1H, d, ⁴*J*_{HH} = 1.6 Hz). ¹³C NMR (100 MHz, CDCl₃) δ 26.7, 28.0, 48.3, 52.2, 60.3, 117.5, 124.0, 124.3, 124.6, 127.6, 129.0, 129.9, 130.4, 131.0, 131.2, 136.2, 141.5, 142.7, 149.4, 162.8, 166.5, 167.9, 196.3. HRMS (ESI) calcd for C₂₅H₂₃N₂O₄ ([M+H]⁺), 415.1658; found, 415.1651.

2-(3-methoxycarbonylpyridin-2-yl)-2-(4-trifluoromethylphenyl)acetic acid N-(4-methylphenyl)amide (II g). Pale yellow oil (45 mg, 21%). *R_f* 0.17 (hexanes–AcOEt 2:1). IR (CH₂Cl₂) $\nu_{\max}/\text{cm}^{-1}$ 3303, 3031,

2953, 1729, 1661, 1598, 1515, 1326, 1292, 1165, 1122, 1068, 1019, 818, 747. 2,5-Substituted isomer (major): ^1H NMR (400 MHz, CDCl_3) δ 2.29 (3H, s), 3.96 (3H, s), 5.22 (1H, s), 7.09 (2H, m), 7.42 (2H, m), 7.55 (4H, m), 7.65 (1H, d, $^3J_{\text{HH}} = 8.0$ Hz), 8.31 (1H, dd, $^3J_{\text{HH}} = 8.1$ Hz, $^4J_{\text{HH}} = 2.0$ Hz), 9.27 (1H, d, $^4J_{\text{HH}} = 1.6$ Hz), 10.03 (1H, bs). ^{13}C NMR (100 MHz, CDCl_3) δ 20.8, 52.5, 60.8, 120.0, 123.9 (q, $^1J_{\text{CF}} = 272.2$ Hz), 124.4, 125.2, 125.8 (q, $^3J_{\text{CF}} = 3.8$ Hz), 128.6, 129.4, 130.0 (q, $^2J_{\text{CF}} = 32.3$ Hz), 134.2, 135.1, 138.7, 141.9, 150.2, 161.8, 165.1, 166.8. ^{19}F NMR (376 MHz, CDCl_3) δ -62.69 (s). 2,3-Substituted isomer (minor): ^1H NMR (400 MHz, CDCl_3) δ 2.28 (3H, s), 3.92 (3H, s), 6.30 (1H, s), 7.09 (2H, m), 7.37 (1H, dd, $^3J_{\text{HH}} = 7.8$ Hz, 4.8 Hz), 7.42 (2H, m), 7.55 (4H, m), 8.28 (1H, dm, $^3J_{\text{HH}} = 8.0$ Hz), 8.80 (1H, dd, $^3J_{\text{HH}} = 4.7$ Hz, $^4J_{\text{HH}} = 1.6$ Hz), 9.71 (1H, bs). ^{13}C NMR (100 MHz, CDCl_3) δ 20.8, 52.8, 56.5, 119.9, 122.3, 125.4 (q, $^3J_{\text{CF}} = 3.7$ Hz), 126.5, 128.6, 129.4, 133.9, 135.3, 139.5, 142.4, 151.5, 158.2, 166.3, 167.6. ^{19}F NMR (376 MHz, CDCl_3) δ -62.60 (s). HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{20}\text{N}_2\text{O}_3\text{F}_3$ ($[\text{M}+\text{H}]^+$), 429.1426; found, 429.1420.

Synthesis and characterization amide 10j. This compound was obtained using the same two-step procedure as described for **10i** and **4j** (see main text), but with the first step (reaction of **1b** and **2j** at 70 °C) lasting 30 min and using 4-aminobutyric aldehyde diethyl acetal (1.14 mmol, 184 mg, 197 μL) instead of *p*-toluidine, in 287 mg (65%) yield as pale yellow oil. R_f 0.22 (hexanes–AcOEt 5:1). IR (CH_2Cl_2) $\nu_{\text{max}}/\text{cm}^{-1}$ 3357, 3186, 2969, 1690, 1515, 1446, 1390, 1213, 1173, 1155, 1061, 828. ^1H NMR (400 MHz, CDCl_3) δ 1.20 (6H, t, $^3J_{\text{HH}} = 6.6$ Hz), 1.25 (9H, s), 1.64 (3H, s), 1.71 (4H, m), 2.25 (6H, s), 3.34 (2H, m), 3.51 (2H, m), 3.66 (2H, m), 4.53 (1H, t, $^3J_{\text{HH}} = 5.3$ Hz), 6.16 (1H, dd, $^3J_{\text{HH}} = 8.0$ Hz, $^4J_{\text{HH}} = 1.9$ Hz), 6.68 (2H, d, $^3J_{\text{HH}} = 8.2$ Hz), 6.92 (3H, m), 7.01 (2H, d, $^3J_{\text{HH}} = 8.6$ Hz), 9.82 (1H, t, $^3J_{\text{HH}} = 5.3$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 9.3, 12.5, 15.2, 20.8, 24.2, 30.9, 31.1, 34.1, 39.8, 61.0, 61.1, 62.4 (q, $^2J_{\text{CF}} = 24.9$ Hz), 102.5, 124.3 (q, $^1J_{\text{CF}} = 286.4$ Hz), 124.7, 127.3, 127.8, 127.9, 128.3, 128.6, 129.0, 131.0, 132.0, 134.2, 137.2, 139.8, 149.9, 165.9. ^{19}F NMR (376 MHz, CDCl_3) δ -63.26 (s). HRMS (ESI) calcd for $\text{C}_{33}\text{H}_{45}\text{N}_3\text{O}_3\text{F}_3$ ($[\text{M}+\text{H}]^+$), 588.3413; found, 588.3420.

Characterization data for 2-alkylimidazoles 4

1-(1-Benzyl-4,5-dimethylimidazol-2-yl)-1-(4-trifluoromethylphenyl)ethane (4h). Pale yellow oil. R_f 0.28 (hexanes–AcOEt 1:1). IR (CH_2Cl_2) $\nu_{\text{max}}/\text{cm}^{-1}$ 2926, 1432, 1325, 1164, 1123, 1071, 1017, 843, 729. ^1H NMR (400 MHz, CDCl_3) δ 1.67 (3H, d, $^3J_{\text{HH}} = 7.2$ Hz), 1.99 (3H, s), 2.25 (3H, s), 4.00 (1H, q, $^3J_{\text{HH}} =$

7.1 Hz), 4.79 (2H, AB, $^2J_{\text{HH}} = 17.2$ Hz), 6.75 (2H, m), 7.21 (5H, m), 7.43 (2H, d, $^3J_{\text{HH}} = 8.1$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 8.7, 12.8, 21.7, 38.1, 46.4, 122.8, 124.1 (q, $^1J_{\text{CF}} = 271.0$ Hz), 125.4, 125.5 (q, $^3J_{\text{CF}} = 3.7$ Hz), 127.4, 127.5, 128.6 (q, $^2J_{\text{CF}} = 32.3$ Hz), 128.7, 132.0, 136.4, 147.4, 148.2. ^{19}F NMR (376 MHz, CDCl_3) δ -62.45 (s). MS (EI 70 eV, m/z , %) 358 (M^+ , 77), 343 (35), 267 (43), 91 (100). HRMS (EI) calcd for $\text{C}_{21}\text{H}_{21}\text{N}_2\text{F}_3$ (M^+), 358.1657; found, 358.1654.

1-(4,5-Dimethyl-1-p-tolylimidazol-2-yl)-1-(3-nitrophenyl)ethane (4i'). Pale yellow crystals (62 mg, 25% from 0.75 mmol of **2i**), mp 99–101 °C (isooctane– CH_2Cl_2). R_f 0.19 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$ 2918, 2860, 1536, 1424, 1348, 807, 730. ^1H NMR (400 MHz, CDCl_3) δ 1.68 (3H, d, $^3J_{\text{HH}} = 7.3$ Hz), 1.85 (3H, s), 2.24 (3H, s), 2.39 (3H, s), 4.01 (1H, q, $^3J_{\text{HH}} = 7.3$ Hz), 6.42 (1H, m), 7.04 (2H, m), 7.27 (1H, m), 7.34 (1H, t, $^3J_{\text{HH}} = 7.8$ Hz), 7.41 (1H, d, $^3J_{\text{HH}} = 7.6$ Hz), 7.68 (1H, t, $^4J_{\text{HH}} = 2.0$ Hz), 7.96 (1H, dm, $^3J_{\text{HH}} = 8.1$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 9.1, 12.7, 21.1, 21.2, 37.8, 121.2, 122.4, 123.9, 127.5, 129.1, 129.9, 132.0, 133.5, 133.8, 139.0, 146.4, 147.4, 148.0. HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{22}\text{N}_3\text{O}_2$ ($[\text{M}+\text{H}]^+$), 336.1712; found, 336.1710. Anal. calcd for $\text{C}_{20}\text{H}_{21}\text{N}_3\text{O}_2$: C, 71.62; H, 6.31; N, 12.53. Found: C, 71.42; H, 6.51; N, 12.48.

Characterization data for side products 6, 7, 8

1,1-Bis(diethylamino)-2-(4-methoxycarbonylphenyl)ethene (6). Yellow oil (54 mg, 35%). R_f 0.10 (AcOEt). IR (CH_2Cl_2) $\nu_{\text{max}}/\text{cm}^{-1}$ 2968, 1712, 1571, 1546, 1432, 1275, 1171, 1102, 778. ^1H NMR (400 MHz, CDCl_3) δ 1.06 (6H, q, $^3J_{\text{HH}} = 7.0$ Hz), 3.02 (2H, q, $^3J_{\text{HH}} = 7.1$ Hz), 3.08 (2H, d, $^3J_{\text{HH}} = 7.0$ Hz), 3.85 (3H, s), 4.56 (1H, s), 7.04 (2H, d, $^3J_{\text{HH}} = 8.5$ Hz), 7.82 (2H, d, $^3J_{\text{HH}} = 8.5$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 12.0, 13.3, 42.5, 43.2, 51.5, 90.4, 122.1, 124.5, 129.4, 146.5, 155.8, 167.5. HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{29}\text{N}_2\text{O}_2$ ($[\text{M}+\text{H}]^+$), 305.2229; found, 305.2228.

Methyl 4-(2,2,2-trifluoroethyl)benzoate (7).⁷ Colourless oil. R_f 0.72 (hexanes–AcOEt 2:1). ^1H NMR (400 MHz, CDCl_3) δ 3.43 (1H, q, $^3J_{\text{HF}} = 10.7$ Hz), 3.92 (3H, s), 7.38 (2H, d, $^3J_{\text{HH}} = 8.1$ Hz), 8.03 (2H, d, $^3J_{\text{HH}} = 8.3$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 40.3 (q, $^2J_{\text{CF}} = 30.0$ Hz), 52.2, 125.4 (q, $^1J_{\text{CF}} = 277.3$ Hz), 129.9, 130.1, 130.2, 135.1 (q, $^3J_{\text{CF}} = 2.9$ Hz), 166.6. ^{19}F NMR (376 MHz, CDCl_3) δ -65.57 (t, $^3J_{\text{FH}} = 10.2$ Hz).


N-(4-methoxycarbonylphenylacetyl)indoline (8). White crystals, mp 107–108 °C (isooctane– CH_2Cl_2). R_f 0.67 (hexanes–AcOEt 2:1). IR (KBr) $\nu_{\text{max}}/\text{cm}^{-1}$ 3416, 3312, 3065, 2947, 1717, 1662, 1599, 1482, 1395, 1276, 1185, 1109, 1022, 759, 743. ^1H NMR (400 MHz, CDCl_3) δ 3.17 (2H, t, $^3J_{\text{HH}} = 8.3$ Hz), 3.86

(2H, s), 3.91 (3H, s), 4.07 (2H, t, $^3J_{\text{HH}} = 8.3$ Hz), 7.02 (1H, t, $^3J_{\text{HH}} = 7.4$ Hz), 7.19 (2H, m), 7.39 (2H, d, $^3J_{\text{HH}} = 8.1$ Hz), 8.02 (2H, d, $^3J_{\text{HH}} = 8.1$ Hz), 8.24 (1H, d, $^3J_{\text{HH}} = 8.1$ Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 28.1, 43.4, 48.2, 52.1, 117.2, 124.0, 124.5, 127.6, 129.0, 129.2, 130.0, 131.0, 139.5, 142.9, 166.9, 168.2. MS (EI 70 eV, m/z , %) 295 (M^+ , 45), 264 (100), 236 (57). HRMS (EI) calcd for $\text{C}_{18}\text{H}_{17}\text{NO}_3$ (M^+), 295.1208; found, 295.1206.



Synthesis and characterization of 1-Fluoro-2-(4-tert-butylphenyl)ethene 13. A solution of 1,1-difluoro-2-(4-*tert*-butylphenyl)ethene **2b** (0.5 mmol, 98 mg) in THF (1 mL) was prepared in a flame dried Schlenk flask under argon atmosphere and cooled to -78 °C. Sodium bis(2-methoxyethoxy)aluminum hydride (0.28 mmol, 89 μL of 60% solution in toluene) was added dropwise. After 5 min of stirring the cooling bath was removed and the reaction allowed to warm to rt over about 30 min. Saturated aqueous NH_4Cl (1 mL) was added with vigorous stirring and then the reaction mixture was separated between brine (5 mL) and *n*-pentane (5 mL). The two layers were separated, the aqueous phase was washed with *n*-pentane (2 mL) and the combined organic phases were washed with brine (5 mL), dried over anhydrous Na_2SO_4 and evaporated. After column chromatography on silica gel with *n*-pentane as eluent 76 mg (85%) of fluorostyrene **13** was obtained as an inseparable 12.5:1 mixture of *E* and *Z* isomers; pale yellow oil. IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 2964, 1659, 1110, 1089, 912, 559. HRMS (ESI) calcd for $\text{C}_{12}\text{H}_{16}\text{F}$ ($[\text{M}+\text{H}]^+$), 179.1236; found, 179.1239. Isomer *E*: ^1H NMR (400 MHz, CDCl_3) δ 1.32 (9H, s), 6.37 (1H, dd, $^3J_{\text{HF}} = 19.4$ Hz, $^3J_{\text{HH}} = 11.4$ Hz), 7.14 (1H, dd, $^2J_{\text{HF}} = 83.6$ Hz, $^3J_{\text{HH}} = 11.4$ Hz), 7.18 (2H, m), 7.33 (2H, m). ^{13}C NMR (100 MHz, CDCl_3) δ 31.2, 34.5, 113.5 (d, $^2J_{\text{CF}} = 15.7$ Hz), 125.7, 125.9 (d, $^4J_{\text{CF}} = 2.8$ Hz), 129.7 (d, $^3J_{\text{CF}} = 11.8$ Hz), 149.8 (d, $^1J_{\text{CF}} = 257.5$ Hz), 150.6 (d, $J_{\text{CF}} = 1.8$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -131.00 (dd, $^2J_{\text{FH}} = 83.8$ Hz, $^3J_{\text{FH}} = 19.4$ Hz). *Z*: ^1H NMR (400 MHz, CDCl_3) δ 1.30 (9H, s), 5.58 (1H, dm, $^3J_{\text{HF}} = 45.0$ Hz), 6.61 (1H, dd, $^2J_{\text{HF}} = 83.0$ Hz, $^3J_{\text{HH}} = 5.2$ Hz), 7.37 (2H, m), 7.48 (2H, m). ^{19}F NMR (376 MHz, CDCl_3) δ -123.17 (dd, $^2J_{\text{FH}} = 82.6$ Hz, $^3J_{\text{FH}} = 45.3$ Hz).

References


1. S. A. Fuqua, W. G. Duncan and R. M. Silverstein, *J. Org. Chem.*, 1965, **30**, 1027–1029.
2. R. Loska, K. Szachowicz and D. Szydlik, *Org. Lett.*, 2013, **15**, 5706–5709.
3. V. G. Nenajdenko, G. N. Varseev, V. N. Korotchenko, A. V. Shastin and E. S. Balenkova, *J. Fluorine Chem.*, 2003, **124**, 115–118.
4. T. Ichitsuka, T. Takanohashi, T. Fujita and J. Ichikawa, *J. Fluorine Chem.*, 2015, **170**, 29–37.
5. X.-P. Wang, J.-H. Lin, J.-C. Xiao and X. Zheng, *Eur. J. Org. Chem.* **2014**, 928–932.
6. R. Ocampo, W. R. Dolbier, Jr. and R. Paredes, *J. Fluorine Chem.*, 1998, **88**, 41–50.
7. G. Wu, Y. Deng, C. Wu, X. Wang, Y. Zhang and J. Wang, *Eur. J. Org. Chem.*, 2014, 4477–4481.




2b: ^1H NMR (400 MHz, CDCl_3)





2b: ^{13}C NMR (100 MHz, CDCl_3)










2b: ^{19}F NMR (470 MHz, CDCl_3)




2c: ^1H NMR (400 MHz, CDCl_3)














2e: ^{19}F NMR (376 MHz, CDCl_3)




2g: ^1H NMR (400 MHz, CDCl_3)






7.610
7.609
7.589
7.477
7.457
7.455
7.243



2h: ¹H NMR (400 MHz, CDCl₃)

1.996
1.987
1.979

-0.000






156.77
153.91
153.86
151.00
138.65
129.67
129.34
129.02
128.15
127.79
127.76
127.74
127.71
125.45
125.36
125.33
125.29
125.25
122.74
120.04

87.18
87.04
86.95
86.81
77.32
77.00
76.68


12.95

2h: ¹³C NMR (100 MHz, CDCl₃)







2h: ^{19}F NMR (376 MHz, CDCl_3)







7.49
7.49
7.48
7.47
7.30
7.28







2j: ^1H NMR (400 MHz, $\text{THF-}d_8$)



















3d: ^1H NMR (200 MHz, CDCl_3)





3d: ^{13}C NMR (50 MHz, CDCl_3)







5a: ^1H NMR (500 MHz, CDCl_3)





5a: ^{13}C NMR (125 MHz, CDCl_3)










5b: ¹H NMR (500 MHz, CDCl₃)







5b: ¹³C NMR (100 MHz, CDCl₃)

























9d: ¹H NMR (500 MHz, CDCl₃)




9d: ¹³C NMR (125 MHz, CDCl₃)







9.489
8.328
8.311
7.837
7.821
7.736
7.720
7.570
7.568
7.554
7.540
7.516
7.501
7.487
7.346
7.332
7.316
7.293
7.279
7.279
7.243
7.135
7.128
7.122
6.960
6.958
6.944
6.930
6.928
6.753
6.694
6.692
6.684
6.678
6.627
6.611
6.596
5.758
4.789
4.755
4.723
4.689
4.639
4.515
4.330
4.316



9g: ^1H NMR (500 MHz, CDCl_3)



9g: ^{13}C NMR (125 MHz, CDCl_3)

